
Hereditary Cancer Syndromes > GALNT12, RPS20
NCCN Guidelines
RECOMMEND TESTING FOR ANY PROSTATE CANCER PATIENTS WITH AT LEAST ONE OF THE FOLLOWING:
-
Intraductal histology (tends to be associated with more aggressive disease)
-
Ashkenazi Jewish ancestry
-
3 or more cancers on the same side of the family (HBOC or Lynch Syndrome type cancers including bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, and/or urothelial cancer)
-
Family history of young (<60) or fatal prostate cancer regardless of pathology or grade
-
T3 or T4 disease
-
Regional or metastatic disease
-
Grade group 4 or 5*
-
PSA > 20ng/ml
GENETIC TESTING SHOULD INCLUDE THE FOLLOWING GENES (Consider NGS Panel Testing):
ATM, BRCA1, BRCA2, CHEK2, HOXB13**, MLH1, MSH2, MSH6, PALB2, and PMS2

CANCER
GENETIC CANCER RISK
Prostate
High Risk

CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATIONÂ *
Prostate
Recommend prostate cancer screening.
40 years, or 10 years younger than the earliest prostate cancer diagnosis in the family
Annually, or adjusted based on results from first PSA screen

CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATIONÂ *
Prostate
Recommend prostate cancer screening.
40 years, or 10 years younger than the earliest prostate cancer diagnosis in the family
Annually, or adjusted based on results from first PSA screen